<DOC>
	<DOCNO>NCT02844842</DOCNO>
	<brief_summary>This observational prospective study assess tolerability safety treatment SCIT Allergovac Poliplus polymerize depot presentation . The study drug administer either 1 day Schedule rapid Schedule ( 3 increase weekly dos initiation period till maintenance dose reach ) The study population : adult child , polysensitized least 2 allergen source rhinitis allergic rhinoconjunctivitis . Patients may also present concomitant mild moderate asthma . The assignment patient particular therapeutic strategy decide advanced trial protocol determine routine clinical practice . The decision investigator prescribe particular treatment clearly dissociate decision include patient study . The patient suffer intervention , whether diagnostic monitoring , usual clinical practice .</brief_summary>
	<brief_title>Evaluation Tolerability Safety `` Allergovac Poliplus '' Polysensitized Patients With Rhinitis Allergic Rhinoconjunctivitis With Without Asthma : A Study Daily Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Patients age 5 60 year present rhinitis allergic rhinoconjunctivitis cause IgEmediated sensitization one allergen source without mild / moderate asthma . 2 . Patients eligible immunotherapy treatment Allergovac Poliplus accord investigator criterion . 3 . Patients must provide write informed consent . It case child , legal representative tutor child must sign inform consent form . 1 . Patients accord investigator criterion may present difficulty understand patient information sheet , complete questionnaire selfadministered scale . 2 . Patients accord investigator may present difficulty complete patient diary . 3 . Patients participate another clinical trial observational study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mild moderate</keyword>
</DOC>